Publication date: Jul 01, 2025

BNT162b2 is a mRNA vaccine, approved by the US Food and Drug Administration and the European Medicines Agency that was designed to target Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 2019 (COVID-19). Despite its widespread use, predictors of humoral immune responses after BNT162b2 administration remain uncertain. Consequently, a case-control study was conducted involving 273 employees at the National Cancer Institute (Bratislava, Slovakia) for the present study. Specifically, the present study aimed to determine the incidence of symptomatic COVID-19. In addition, the association between the safety of the third-dose BNT162b2 and sex and body mass index (BMI) was assessed. The present study also explored the potential determinants of plasma IgG antibody levels following vaccination. In total, 294 participants were recruited and 273 met the inclusion criteria. At a median follow-up of 4. 7 months, 38 participants had symptomatic SARS-CoV-2 infection after vaccination. The incidence of adverse events (AEs) was found to be significantly higher in female patients compared with that in male patients. Furthermore, patients with a high BMI (≥30 kg/m^2) had higher number of AEs compared with those with low BMI (P

Semantics

Original Article